GO:0031716 calcitonin receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0031716 calcitonin receptor binding is a molecular function defined as binding to a calcitonin receptor, with the synonym calcitonin receptor ligand.
• Calcitonin receptor binding is mediated by peptide ligands such as calcitonin, amylin, and dual-acting agonists that engage the calcitonin receptor and related family B GPCRs [1,3,7].
• The calcitonin receptor is a class B G protein-coupled receptor; ligand binding triggers receptor activation and downstream signaling [3,7].
• Calcitonin receptor binding is a key pharmacological target in obesity, migraine, and bone metabolism research [1,4,5,6].
• Experimental models for studying calcitonin receptor binding include receptor-binding assays, knockout and knock-in cell lines, and CRISPR-based screens [2,6,7,8].
• EDITGENE provides CRISPR services to create knockout, point-mutation, knock-in, and overexpression cell models for calcitonin receptor binding research.
Description
GO:0031716 calcitonin receptor binding is a molecular function term in the Gene Ontology that describes the binding of a ligand to a calcitonin receptor. This function is central to understanding how calcitonin-family peptides interact with their receptors and initiate downstream signaling [3,7]. The calcitonin receptor is a class B G protein-coupled receptor (GPCR) that is activated by peptide hormones such as calcitonin and amylin, and its binding properties are critical for both physiological regulation and drug development [3,7]. Researchers study calcitonin receptor binding to dissect receptor pharmacology, identify selective agonists, and develop therapeutics for metabolic and neurological disorders [1,4,5]. The term is also relevant to comparative endocrinology, as shown by studies of calcitonin receptor binding in non-mammalian systems. Because calcitonin receptor binding is a molecular function, it is often investigated using receptor-binding assays, pharmacological profiling, and genetically modified cell models [6,7,8].
calcitonin receptor binding At A Glance
| GO ID | GO:0031716 |
|---|---|
| GO term | calcitonin receptor binding |
| Ontology | molecular_function |
| Synonym | calcitonin receptor ligand |
| Major function | Binding to a calcitonin receptor, enabling ligand-receptor interaction and downstream signaling [3,7]. |
| Related receptors | Calcitonin receptor (CTR), amylin receptors (AMY1, AMY2, AMY3), and related class B GPCRs [1,4,7]. |
| Key ligands | Calcitonin, amylin, cagrilintide, and dual-acting agonists such as BGM1812 [1,4,7]. |
| Physiological roles | Regulation of bone metabolism, energy homeostasis, and neuroendocrine functions [3,4,6]. |
| Therapeutic areas | Obesity, migraine, osteoporosis, and other calcitonin-related disorders [1,4,5,6]. |
What Is GO:0031716?
In the Gene Ontology, GO:0031716 calcitonin receptor binding is defined as the binding to a calcitonin receptor. It is a molecular function term with the synonym calcitonin receptor ligand. This function encompasses the interaction between a ligand (such as a peptide hormone or synthetic agonist) and the calcitonin receptor, leading to receptor occupancy and potential activation [3,7]. The term is distinct from downstream signaling events and focuses specifically on the binding event itself.
Why Is calcitonin receptor binding Important in Cell Biology?
Calcitonin receptor binding is important because it is the first step in the activation of the calcitonin receptor, a class B GPCR that regulates diverse physiological processes including bone resorption, energy balance, and neuroendocrine signaling [3,6,7]. Pharmacological modulation of this binding event is the basis for approved drugs such as eptinezumab for migraine prevention and emerging therapeutics for obesity [1,5]. Understanding the molecular determinants of calcitonin receptor binding enables the design of selective agonists and antagonists with improved efficacy and safety profiles [1,7].
• Calcitonin receptor binding is the initial event in calcitonin receptor activation, a class B GPCR involved in bone and energy metabolism [3,7].
• It is a validated drug target for obesity, with dual amylin and calcitonin receptor agonists such as BGM1812 in development.
• Cagrilintide, a long-acting amylin analog, lowers body weight through brain amylin receptors, highlighting the therapeutic relevance of receptor binding.
• Eptinezumab, a monoclonal antibody targeting CGRP, was approved for migraine prevention, illustrating the clinical impact of targeting calcitonin family receptor pathways.
• Calcitonin receptor binding is a marker of osteoclast heterogeneity in osteopetrotic rodents, linking it to bone biology.
• Receptor N-glycosylation can modulate peptide ligand interaction with the calcitonin gene-related peptide receptor, affecting binding properties.
• Comparative studies in hens show that calcitonin receptor binding in the neurohypophysis changes before and after oviposition, indicating physiological regulation.
• Pharmacological comparison of agonists such as AM833 provides insights into selectivity across calcitonin family GPCRs.
• CRISPR-based models enable precise interrogation of genes involved in calcitonin receptor binding and downstream signaling [6,7,8].
• Understanding calcitonin receptor binding supports the development of next-generation therapeutics for metabolic and neurological disorders [1,4,5].
Molecular Mechanism of calcitonin receptor binding
Ligand recognition and binding interface
In simple terms: The ligand docks onto the receptor like a key in a lock.
Calcitonin receptor binding involves the interaction of peptide ligands with the extracellular domain and transmembrane regions of the calcitonin receptor, a class B GPCR [3,7]. The binding interface typically includes the receptor's N-terminal extracellular domain and extracellular loops, which recognize the C-terminal region of the peptide ligand, while the ligand's N-terminus engages the transmembrane core to trigger activation [3,7]. This two-step binding model is characteristic of class B GPCRs and is supported by pharmacological studies of calcitonin family agonists.
Receptor activation and conformational changes
In simple terms: Once the ligand binds, the receptor changes shape to send a signal inside the cell.
Ligand binding to the calcitonin receptor induces conformational changes that propagate from the extracellular domain to the transmembrane helices, leading to G protein coupling and downstream signaling [3,7]. The binding event stabilizes an active receptor conformation, which can be measured using radioligand binding assays and functional readouts such as cAMP accumulation. The specific conformational dynamics depend on the ligand's structure and the receptor's glycosylation state.
Ligand selectivity and receptor subtypes
In simple terms: Different ligands can prefer different receptor subtypes, like different keys fitting similar locks.
Calcitonin receptor binding is not uniform across all ligands; selectivity arises from differences in the receptor's extracellular domain and the ligand's sequence [1,7]. For example, dual amylin and calcitonin receptor agonists such as BGM1812 are designed to bind both amylin and calcitonin receptors, whereas other agonists may be more selective. Cagrilintide acts through brain amylin receptors 1 and 3, demonstrating subtype-specific binding. Pharmacological comparison of AM833 with other agonists highlights the importance of binding selectivity in drug development.
Regulation by glycosylation and cellular context
In simple terms: Sugar modifications on the receptor can affect how well a ligand binds.
N-glycosylation of the calcitonin gene-related peptide receptor can inhibit peptide ligand interaction, indicating that post-translational modifications regulate calcitonin receptor binding. The cellular context, including the presence of receptor activity-modifying proteins (RAMPs), can also influence binding specificity and affinity [3,7]. These regulatory mechanisms are important for understanding tissue-specific responses to calcitonin-family peptides [2,8].
Binding assays and pharmacological profiling
In simple terms: Scientists use binding assays to measure how strongly a ligand sticks to the receptor.
Calcitonin receptor binding is experimentally assessed using radioligand binding assays, surface plasmon resonance, and functional cAMP assays [6,7]. These methods allow determination of binding affinity, kinetics, and selectivity across receptor subtypes. In osteopetrotic rodent models, calcitonin receptor binding has been used as a marker of osteoclast heterogeneity, demonstrating the utility of binding assays in disease research. Comparative studies in hens have also employed binding assays to study neurohypophyseal calcitonin receptors.
Key Genes Involved in GO:0031716 calcitonin receptor binding
The following genes and proteins are central to calcitonin receptor binding, including receptors, ligands, and associated signaling molecules.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CALCR | Encodes the calcitonin receptor, a class B GPCR that binds calcitonin and amylin [3,7]. | Primary receptor for studying calcitonin receptor binding and drug development [1,7]. |
| CALCA | Encodes calcitonin, the endogenous peptide ligand that binds the calcitonin receptor. | Ligand used in binding assays and physiological studies [2,6]. |
| IAPP | Encodes amylin, a peptide hormone that binds amylin receptors (calcitonin receptor/RAMP complexes). | Target for obesity and diabetes research; amylin analogs are used to study receptor binding. |
| RAMP1 | Encodes receptor activity-modifying protein 1, which modulates calcitonin receptor binding specificity [3,7]. | Determines amylin receptor subtype pharmacology. |
| RAMP2 | Encodes receptor activity-modifying protein 2, involved in receptor trafficking and ligand binding. | Modulates calcitonin receptor function in different tissues. |
| RAMP3 | Encodes receptor activity-modifying protein 3, which forms amylin receptors with CALCR. | Relevant to brain amylin receptor binding and energy homeostasis. |
| CALCRL | Encodes the calcitonin receptor-like receptor, a related class B GPCR [5,8]. | Target of CGRP antibodies and involved in migraine pathophysiology. |
| CRCP | Encodes calcitonin gene-related peptide (CGRP), a ligand for CALCRL/RAMP1. | Studied in migraine and neurogenic inflammation. |
| GPRCAL1 | Putative calcitonin receptor-like GPCR, involved in ligand binding. | Explored in pharmacological profiling of agonists. |
| GNAS | Encodes the Gs alpha subunit that couples to calcitonin receptor upon ligand binding. | Mediates downstream cAMP signaling after receptor binding. |
| ARRB1 | Encodes beta-arrestin 1, which regulates receptor desensitization after ligand binding. | Modulates calcitonin receptor signaling and trafficking. |
| ARRB2 | Encodes beta-arrestin 2, involved in receptor internalization. | Affects duration of calcitonin receptor signaling. |
| PTH1R | Encodes parathyroid hormone 1 receptor, a related class B GPCR. | Comparative studies of ligand binding specificity. |
| SCTR | Encodes secretin receptor, another class B GPCR. | Used in pharmacological comparisons of peptide binding. |
| VIPR1 | Encodes vasoactive intestinal peptide receptor 1. | Related GPCR for selectivity studies. |
| GCGR | Encodes glucagon receptor, a class B GPCR. | Comparator in binding selectivity assays. |
| GLP1R | Encodes glucagon-like peptide-1 receptor, a class B GPCR. | Target of dual agonists that also bind calcitonin receptor. |
| CTR | Calcitonin receptor protein (product of CALCR). | Used as a marker in osteoclast heterogeneity studies. |
How Is calcitonin receptor binding Regulated?
Calcitonin receptor binding is regulated at multiple levels, including receptor expression, post-translational modifications such as N-glycosylation, and the presence of receptor activity-modifying proteins (RAMPs) that alter ligand specificity [3,7,8]. N-glycosylation of the calcitonin gene-related peptide receptor can inhibit peptide ligand interaction, demonstrating direct regulation of binding. Additionally, physiological states such as oviposition in hens can change calcitonin receptor binding in the neurohypophysis, indicating hormonal regulation. Pharmacological regulation is achieved through agonists and antagonists that compete for the binding site, as seen with dual amylin and calcitonin receptor agonists [1,7].
calcitonin receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CALCR | Obesity and metabolic disorders [1,4] | Knockout and knock-in cell lines for binding assays [1,7] |
| CALCA | Bone metabolism and osteopetrosis | Osteoclast cultures from knockout mice |
| CALCRL | Migraine and neurovascular disorders [5,8] | Overexpression cell models for CGRP binding |
| IAPP | Obesity and diabetes | Amylin receptor binding assays in brain-derived cells |
| RAMP1 | Migraine and CGRP signaling [5,8] | Knock-in models with tagged RAMP1 |
Obesity and metabolic disorders
Calcitonin receptor binding is a key mechanism targeted by anti-obesity therapeutics. Dual amylin and calcitonin receptor agonists such as BGM1812 are being developed for obesity treatment, and their efficacy depends on binding to both amylin and calcitonin receptors. Cagrilintide, a long-acting amylin analog, lowers body weight through brain amylin receptors 1 and 3, highlighting the role of receptor binding in energy homeostasis. These findings underscore the therapeutic potential of modulating calcitonin receptor binding in metabolic diseases [1,4].
Migraine and neurovascular disorders
Calcitonin receptor binding is relevant to migraine pathophysiology through the calcitonin gene-related peptide (CGRP) pathway. Eptinezumab, a monoclonal antibody targeting CGRP, was approved for migraine prevention, demonstrating the clinical importance of blocking CGRP binding to its receptor. The calcitonin receptor-like receptor (CALCRL) and RAMP1 form the CGRP receptor, and ligand binding to this complex is a target for migraine therapeutics [5,8]. N-glycosylation of the CGRP receptor can modulate peptide ligand interaction, affecting binding and potentially disease mechanisms.
Bone metabolism and osteopetrosis
Calcitonin receptor binding is a marker of osteoclast heterogeneity in osteopetrotic rodents, linking it to bone resorption and skeletal disorders. Calcitonin, the endogenous ligand, binds to the calcitonin receptor on osteoclasts to inhibit bone resorption, and alterations in this binding can contribute to bone disease [3,6]. Studying calcitonin receptor binding in osteopetrotic models provides insights into osteoclast function and potential therapeutic targets.
Neuroendocrine and comparative physiology
Calcitonin receptor binding in the hen neurohypophysis changes before and after oviposition, indicating a role in neuroendocrine regulation. This comparative study demonstrates that calcitonin receptor binding is dynamically regulated in response to physiological states, with implications for understanding reproductive and neuroendocrine biology. Such findings highlight the evolutionary conservation and functional diversity of calcitonin receptor binding [2,3].
From calcitonin receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does CALCR knockout abolish calcitonin binding? | CALCR knockout cell line (e.g., HEK293) |
| How does a point mutation in CALCR affect ligand affinity? | Point-mutation knock-in cell line |
| Can a tagged calcitonin receptor be used for imaging binding? | Knock-in of fluorescent or epitope tag |
| What is the effect of CALCR overexpression on signaling? | Overexpression cell line |
| Which genes regulate calcitonin receptor binding? | CRISPR library screening in receptor-expressing cells |
| How does RAMP1 modulate ligand selectivity? | RAMP1 knockout or overexpression models [3,7] |
How to Study the calcitonin receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding assay | Binding affinity and kinetics [6,7] | Characterizing calcitonin receptor ligands |
| cAMP assay | Receptor activation | Functional profiling of agonists |
| CRISPR knockout screen | Genes regulating binding | Discovery of novel modulators |
| Surface plasmon resonance | Real-time binding kinetics | Ligand-receptor interaction studies |
| Immunohistochemistry | Receptor localization [2,6] | Tissue-specific binding studies |
| Fluorescence microscopy | Tagged receptor binding | Live-cell imaging of binding |
| Western blot | Receptor expression levels | Validation of knockout/overexpression |
| qPCR | Gene expression | Quantifying receptor and ligand mRNA |
Radioligand binding assays
Radioligand binding assays are the gold standard for measuring calcitonin receptor binding affinity and kinetics [6,7]. These assays use radioiodinated calcitonin or amylin analogs to quantify specific binding to membrane preparations or whole cells. They enable determination of dissociation constants (Kd) and competition profiles for novel ligands.
Functional cAMP assays
Functional assays measuring cAMP accumulation are used to assess calcitonin receptor activation following ligand binding. These assays complement binding data by linking receptor occupancy to downstream signaling [3,7]. They are particularly useful for characterizing agonist efficacy and potency.
CRISPR-based genetic screens
CRISPR library screening can identify genes that regulate calcitonin receptor binding and signaling. By knocking out candidate genes in receptor-expressing cells, researchers can uncover novel modulators of binding. This approach is powerful for unbiased discovery of binding regulators.
Imaging and tagged receptor models
Tagged knock-in models expressing fluorescent or epitope-tagged calcitonin receptors allow visualization of receptor localization and binding in live cells. These models are valuable for studying receptor trafficking and binding dynamics. They can be combined with advanced microscopy to quantify binding events.
How CRISPR Can Be Used to Study GO:0031716 calcitonin receptor binding
Knockout
CRISPR knockout of CALCR or related genes (e.g., RAMP1) can abolish calcitonin receptor binding, providing a clean background to study ligand specificity. Knockout cell lines are essential for validating binding targets and for identifying off-target effects of agonists. These models can be used in radioligand binding assays to confirm receptor dependence [6,7].
Point Mutation
Point mutations in the calcitonin receptor can be introduced using CRISPR to study the impact of specific amino acid residues on ligand binding. For example, mutations in the receptor's extracellular domain can alter binding affinity and selectivity. Such models are valuable for structure-function studies and for understanding genetic variants associated with disease.
Knock-in
Knock-in of tagged calcitonin receptors (e.g., fluorescent or epitope tags) allows real-time visualization of binding and trafficking. Tagged knock-in models can be used in imaging-based binding assays and to study receptor dynamics. They also facilitate co-immunoprecipitation and proteomic analysis of binding complexes.
Overexpression
Overexpression of calcitonin receptor or its ligands can enhance binding signals for biochemical assays. Overexpression models are useful for screening novel agonists and for producing recombinant receptor for structural studies [1,7]. They can also be used to study the effects of receptor density on binding pharmacology.
How EDITGENE Supports calcitonin receptor binding Research
Researchers studying calcitonin receptor binding-related genes often need to determine whether a candidate gene is causally involved in ligand binding, receptor activation, or downstream signaling. EDITGENE provides a comprehensive suite of CRISPR-based services to create precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for calcitonin receptor binding research.
Frequently Asked Questions About calcitonin receptor binding
What is GO:0031716 calcitonin receptor binding?
GO:0031716 is a Gene Ontology molecular function term defined as binding to a calcitonin receptor, with the synonym calcitonin receptor ligand.
What genes are involved in calcitonin receptor binding?
Key genes include CALCR (calcitonin receptor), CALCA (calcitonin), IAPP (amylin), and RAMP1-3 (receptor activity-modifying proteins) [3,4,7].
What is the function of calcitonin receptor binding?
It mediates the interaction of peptide ligands with the calcitonin receptor, initiating downstream signaling involved in bone metabolism, energy homeostasis, and neuroendocrine regulation [3,6,7].
Which diseases are associated with calcitonin receptor binding?
Obesity, migraine, osteoporosis, and osteopetrosis are associated with calcitonin receptor binding [1,4,5,6].
How is calcitonin receptor binding studied?
It is studied using radioligand binding assays, cAMP functional assays, CRISPR screens, and imaging with tagged receptors [6,7,8].
What are calcitonin receptor agonists?
Calcitonin receptor agonists are ligands that bind and activate the receptor; examples include calcitonin, amylin analogs, and dual agonists like BGM1812 [1,4,7].
What is the role of RAMP proteins in calcitonin receptor binding?
RAMPs modulate the binding specificity and pharmacology of calcitonin receptors, forming amylin receptor subtypes [3,4,7].
Can CRISPR be used to study calcitonin receptor binding?
Yes, CRISPR knockout, knock-in, and point-mutation models are used to dissect the molecular determinants of calcitonin receptor binding [7,8].
What is the clinical relevance of calcitonin receptor binding?
It is the basis for drugs like eptinezumab for migraine and emerging anti-obesity therapeutics targeting amylin and calcitonin receptors [1,5].
How does glycosylation affect calcitonin receptor binding?
N-glycosylation of the CGRP receptor can inhibit peptide ligand interaction, thereby regulating binding.
Conclusion
GO:0031716 calcitonin receptor binding is a fundamental molecular function that underpins the pharmacology of calcitonin-family peptides and their receptors. It is central to physiological processes such as bone metabolism and energy homeostasis, and it is a validated target for therapeutic development in obesity and migraine [1,4,5,6]. Advances in CRISPR-based models and binding assays continue to elucidate the molecular details of this interaction, offering new opportunities for drug discovery [7,8]. Researchers can leverage EDITGENE's services to create tailored cell models and accelerate their investigations into calcitonin receptor binding.
References
- 1. Zong L et al.. 2025. Discovery of BGM1812, a Novel Dual Amylin and Calcitonin Receptor Agonist for Obesity Treatment.. J Med Chem 68(14):14907-14918 PMID: 40608546
- 2. Nakayama H et al.. 2010. Calcitonin receptor binding in the hen neurohypophysis before and after oviposition.. Poult Sci 89(7):1473-80 PMID: 20548075
- 3. Young A. 2005. Receptor pharmacology.. Adv Pharmacol 52:47-65 PMID: 16492540
- 4. Carvas AO et al.. 2025. Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3.. EBioMedicine 118:105836 PMID: 40609154
- 5. Dhillon S. 2020. Eptinezumab: First Approval.. Drugs 80(7):733-739 PMID: 32266704
- 6. Rouleau MF et al.. 1986. Calcitonin receptor binding as a marker of osteoclast heterogeneity in osteopetrotic rodents.. J Bone Miner Res 1(6):543-53 PMID: 2845732
- 7. Fletcher MM et al.. 2021. AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists.. J Pharmacol Exp Ther 377(3):417-440 PMID: 33727283
- 8. Lee S. 2022. Peptide ligand interaction with maltose-binding protein tagged to the calcitonin gene-related peptide receptor: The inhibitory role of receptor N-glycosylation.. Peptides 150:170735 PMID: 35007660
